Hikal starts construction of multiproduct API plant

Published: 28-Oct-2011
Manufacturing Ingredients

Will be operational by June 2012

Hikal, an Indian supplier of active ingredients and intermediates to the pharmaceutical industry, has started construction of a new multipurpose, multiproduct API plant, which will be operational by June 2012.

The flexible plant will be able to manufacture four APIs simultaneously under GMP and consists of two parallel streams running simultaneously with quick changeover capability.

The plant will also be able to accommodate 32 reactors with capacities ranging from 6m3 to 10m3, resulting in a total reactor volume of approximately 300m3.

A wide range of reactions will be carried out in the new plant, including nitration, liquid phase Oppenauer oxidation, Swern oxidation, Suzuki reaction, chiral synthesis, Mannich reaction, Friedel Craft reactions and more.

The firm says the reactors will be a combination of stainless steel and glass lined. Equipment for isolation and drying such as agitated nutsch filters, centrifuges and various types of dryers will also be installed.

Hikal has five manufacturing facilities in India at Maharashtra (Taloja and Mahad), Gujarat (Panoli) and Bangalore (Jigani), including an r&D centre and a dedicated contract research facility, Acoris Research, in Pune.

See more

You may also like

Ingredients

Hikal completes third US FDA audit in Bangalore

Read more
Indian ingredients manufacturer will ramp up new products under validation

Trending Articles

  1. FDA issues first cGMP warning letter citing AI misuse in pharmaceutical manufacturing A Michigan-based lab has become the subject of the FDA's first dedicated enforcement action on artificial intelligence misuse in drug manufacturing — a landmark event with far-reaching implications for cGMP compliance across the pharmaceutical supply chain
  2. Japanese pharma companies shifting to earlier CDMO outsourcing as peptide complexity increases Neuland Laboratories has reported a notable shift in Japanese pharmaceutical outsourcing patterns during the past 12-24 months, with companies engaging CDMOs earlier in the development cycle
  3. UK REACH reform falls short as industry warns of £500m+ compliance bill The UK chemicals industry has condemned the Government's long-awaited response to the UK REACH Alternative Transitional Registration model consultation, arguing it does little to support growth or innovation
  4. See. Try. Believe. Experience the Lyza 7000 FTIR with a 70-day risk free trial Laboratories can now evaluate the Lyza 7000 FTIR spectrometer in their own environment through a new 70-day, no-cost, no-risk trial program. The initiative allows teams to run real samples, follow existing SOPs, and fully explore the instrument’s capabilities before making a purchase decision
  5. Andelyn Biosciences and ENCell partner to create US-APAC gene therapy manufacturing corridor The company has signed a collaboration agreement with South Korea's ENCell to establish a dual-hemisphere manufacturing platform linking US and Asia-Pacific facilities, enabling in-country production for regional clinical trials

Upcoming event

CHEMUK 2026

20–21 May 2026 | Conference and Exhibition | Birmingham, UK See all

You may also like

Ingredients

Hikal completes third US FDA audit in Bangalore

Indian ingredients manufacturer will ramp up new products under validation
Media

Acoris and c-LEcta to develop synthetic routes for chiral compounds

<p>Acoris Research, a subsidiary of Hikal, and c-LEcta, a German industrial biotech company, are to collaborate on developing synthetic routes for chiral compounds. The partnership combines the expertise of Acoris in process development and small-scale manufacturing with the biocatalysis technologies of c-LEcta.</p>
Ingredients

Hikal signs API contract manufacturing agreement with Pfizer

<p>Indian outsourcing company Hikal has completed a contract manufacturing agreement for supply of active pharmaceutical ingredients (APIs) with Pfizer. Terms of the agreement were not disclosed.</p>
Manufacturing

BD and Suttons Creek collaborate to streamline combination product development for pharma and biotech

The new strategic collaboration will help pharmaceutical and biotech companies reduce development risk and regulatory complexity across drug-device combination products, including biologics and GLP-1 therapies
Manufacturing

Miltenyi Biotec and CHA Biotech collaborate on BaEV lentiviral vector platform

The pair will work to enhance CAR NK cell therapy manufacturing efficiency, combining Miltenyi Bioindustry's baboon envelope lentiviral vector platform with CHA Biotech's NK cell research expertise to improve gene delivery, scalability and cost of goods
Manufacturing

Piramal Pharma Solutions and Ajinomoto Bio-Pharma Services collaborate to support ADC development and manufacturing

Piramal and Ajinomoto Bio-Pharma Services have entered a collaborative arrangement aimed at enhancing their customers’ ADC development and manufacturing programs
Manufacturing

Cipla receives FDA approval for first AB-rated generic of Ventolin HFA in $1.5bn US albuterol market

Indian pharmaceutical company Cipla has secured final FDA approval for its Albuterol Sulfate Inhalation Aerosol, becoming the first AB-rated generic therapeutic equivalent of GlaxoSmithKline's Ventolin HFA
Subscribe now